About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

TERMINATEDPhase 1NCT00985374

A Multiple Ascending Dose Study of the mTOR Inhibitor (RAD001) in Combination With R1507 in Patients With Advanced Solid Tumors

This 2 part study will assess the safety, tolerability and efficacy of a combination of oral daily RAD001 and intravenous 3-weekly R1507 in patients with advanced solid tumors. In Part 1 of the study,...

Lead sponsor: Hoffmann-La Roche•2 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Hoffmann-La Roche

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•adult patients, \>=18 years of age;
•histologically confirmed recurrent or refractory advanced solid tumor (Part 1);
•advanced metastatic renal cell cancer OR advanced metastatic pancreatic neuroendocrine tumors, with evidence of progressive disease (Part 2);
•measurable disease (Part 2);
•ECOG performance status 0-2.

Exclusion Criteria

•prior treatment with agents acting via inhibition of IGF-IR pathway;
•prior treatment with agents acting via inhibition of mTOR (Part 2);
•untreated CNS metastases;
•current anti-cancer therapy, or radiotherapy or chemotherapy \<=4 weeks prior to enrollment;
•other known malignancy requiring treatment.

Related studies

DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns

NCT07109154 · Lung Neoplasms

RECRUITINGPhase 3

A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer

NCT06919965 · Non-Muscle Invasive Bladder Neoplasms

RECRUITINGPhase 1/2

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

NCT06380816 · Advanced Solid Tumours, Squamous Cell Carcinoma of Head and Neck, and more

Biospecimen Procurement for Head and Neck Disorders

NCT03429036 · Hearing Disorder, Oral Mucosal Disease, and more

RECRUITINGPhase 2

Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma

NCT03206060 · Pheochromocytoma, Paraganglioma, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: November 2, 2016Terms

Trial snapshot

StatusTERMINATED

PhasePHASE1

Enrollment11

Start dateNov 2009

Last updatedNov 2, 2016

Condition

Locations shown

New York, New York

San Antonio, Texas

Milan, Lombardy

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 2, 2016Data synced to Clareo: May 17, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions